Dapaglifozin

Phase 3Small molecule

AstraZeneca

Dapaglifozin is one of 62 small molecule programs targeting Septic Shock. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Type 2 DiabetesActive, not recruiting

Septic ShockPhase 3

Active, not recruiting

Type 2 DiabetesPhase 2

Active, not recruiting

Competition

Competitive Landscape

885 competitors in Type 2 Diabetes

#DrugCompanyPhaseTrials

Byetta

AstraZeneca

Preclinical

55 2

Jardiance

Boehringer Ingelheim

Preclinical

31 3

Dapaglifozin

AstraZeneca

Phase 3

1 4

NOVOLIN R

Novo Nordisk

Preclinical

5 5

Glargine

Eli Lilly

Preclinical

8 6

Inspra

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

2 7

Aurlumyn

BBTG International Inc.

Preclinical

1 8

Nexium

DDexcel Pharma Technologies Ltd.

Preclinical

1 9

Inderal

WWyeth-Lederle Vaccines

Preclinical

1 10

Pravachol

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 3Not yet recruiting

Septic Shock

NCT07488689

Clinical

Trials by Indication[1]

Septic Shock1 trial

Assessing the Efficacy of Dapagliflozin as a Vasculoprotective Treatment in Septic Shock Patients With Microcirculatory Dysfunction

Not yet recruiting·UUniversity Hospital, Strasbourg, France·Phase 3·NCT07488689·568 enrolled

Type 2 Diabetes1 trial

Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT03444584·49 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Dapaglifozin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Dapaglifozin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Dapaglifozin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — AstraZeneca company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: AstraZeneca

Dapaglifozin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Septic Shock1 trial

Type 2 Diabetes1 trial

References

Drug Info

Quick Facts

Related News